Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of ecnoglutide injection in obesity with knee osteoarthritis
CTR20262834Phase 3Active
- Sponsor
- Sciwind Biosciences
- Start
- Aug 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity and knee osteoarthritis (OA) comparing Ecnoglutide with Placebo (2 arms). Primary endpoints: Change from baseline in WOMAC pain score and Percent change from baseline in body weight. Started Aug 2026; status: active.
02
Drugs
ecnoglutide
03
Conditions
obesityknee osteoarthritis (OA)
Beyond the preview
Go deeper on CTR20262834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262834.